We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Not Swayed by Teva’s Argument in Copaxone Citizen’s Petition
FDA Not Swayed by Teva’s Argument in Copaxone Citizen’s Petition
May 21, 2010
The FDA has rejected a second citizen’s petition from Teva Pharmaceutical Industries seeking to prevent the agency from accepting applications for generic versions of its Copaxone multiple sclerosis (MS) treatment until certain conditions are met.